Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-107035
Filing Date
2025-11-05
Accepted
2025-11-05 16:24:57
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10487
2 EXHIBIT I tm2530344d1_ex-1.htm EX-99.1 5843
  Complete submission text file 0001104659-25-107035.txt   18475
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Subject) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-58467 | Film No.: 251454457
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022
Business Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022 (212) 841-4100
INTEGRATED CORE STRATEGIES (US) LLC (Filed by) CIK: 0001319244 (see all company filings)

EIN.: 980330397 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A